Biomarin Pharmaceutical Inc (BMRN.OQ)
BMRN.OQ on NASDAQ Stock Exchange Global Select Market
74.95USD
20 Sep 2019
74.95USD
20 Sep 2019
Change (% chg)
-- (--)
-- (--)
Prev Close
$74.95
$74.95
Open
--
--
Day's High
--
--
Day's Low
--
--
Volume
--
--
Avg. Vol
446,236
446,236
52-wk High
$106.69
$106.69
52-wk Low
$70.90
$70.90
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2019 | Jun '19 | 387.76 | -0.209 |
| Mar '19 | 400.74 | -0.317 | |
| FY 2018 | Dec '18 | 353.21 | -0.021 |
| Sep '18 | 391.71 | -0.071 | |
| Jun '18 | 372.85 | -0.095 | |
| Mar '18 | 373.45 | -0.277 | |
| FY 2017 | Dec '17 | 358.30 | -0.052 |
| Sep '17 | 334.15 | -0.072 | |
| Jun '17 | 317.45 | -0.211 | |
| Mar '17 | 303.74 | -0.094 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-19 | 18 | 453.92 | 484.90 | 428.90 | 431.25 |
| Quarter Ending Dec-19 | 18 | 452.25 | 466.50 | 417.00 | 449.38 |
| Year Ending Dec-19 | 22 | 1,696.45 | 1,719.72 | 1,681.00 | 1,744.18 |
| Year Ending Dec-20 | 22 | 1,942.16 | 2,098.10 | 1,821.90 | 2,011.09 |
| Earnings (per share) | |||||
| Quarter Ending Sep-19 | 18 | 0.06 | 0.29 | -0.11 | 0.03 |
| Quarter Ending Dec-19 | 18 | -0.03 | 0.07 | -0.19 | 0.02 |
| Year Ending Dec-19 | 19 | -0.48 | -0.36 | -0.82 | 0.09 |
| Year Ending Dec-20 | 19 | 0.24 | 1.31 | -0.62 | 0.99 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 29.88 | 32.66 | |
| P/E High - Last 5 Yrs. | -- | 42.97 | 47.31 | |
| P/E Low - Last 5 Yrs. | -- | 23.37 | 23.88 | |
| Beta | 1.80 | 0.89 | 0.89 | |
| Price to Sales (TTM) | 13.83 | 6.26 | 7.91 | |
| Price to Book (MRQ) | 5.94 | 5.26 | 5.38 | |
| Price to Tangible Book (MRQ) | 8.07 | 5.93 | 6.71 | |
| Price to Cash Flow (TTM) | -- | 23.51 | 24.36 | |
| % Owned Institutions | -- | 0.75 | 1.45 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 1.42 | 1.35 | |
| Dividend Yield - 5 Year Avg | -- | 1.44 | 1.38 | |
| Dividend 5 Year Growth Rate | -- | 3.90 | 4.54 | |
| Payout Ratio(TTM) | -- | 42.60 | 40.24 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | 5.77 | 5.12 | 12.23 | |
| Sales (TTM) vs TTM 1 Yr. Ago | 23.36 | 6.49 | 7.74 | |
| Sales - 5 Yr. Growth Rate | 20.40 | 10.59 | 10.88 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | 91.80 | 40.58 | 42.97 | |
| EPS (TTM) vs TTM 1 Yr. Ago | 68.48 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 9.78 | 10.31 | |
| Capital Spending - 5 Yr. Growth Rate | -0.77 | 15.44 | 14.84 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | 2.75 | 2.11 | 2.21 |
| Current Ratio (MRQ) | 3.90 | 2.93 | 3.03 |
| LT Debt to Equity (MRQ) | 24.19 | 7.94 | 10.20 |
| Total Debt to Equity (MRQ) | 24.19 | 11.63 | 14.55 |
| Interest Coverage (TTM) | -4.81 | 33.56 | 29.80 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | 81.59 | 51.86 | 52.24 | |
| Gross Margin - 5 Yr. Avg. | 82.35 | 49.68 | 50.41 | |
| EBITD Margin (TTM) | -9.95 | -- | -- | |
| EBITD - 5 Yr. Avg | -15.34 | 17.36 | 13.12 | |
| Operating Margin (TTM) | -17.38 | 13.68 | 6.81 | |
| Operating Margin - 5 Yr. Avg. | -33.82 | 13.91 | 8.92 | |
| Pre-Tax Margin (TTM) | -19.05 | 12.30 | 5.99 | |
| Pre-Tax Margin - 5 Yr. Avg. | -36.93 | 14.32 | 9.22 | |
| Net Profit Margin (TTM) | -14.54 | 9.08 | 2.63 | |
| Net Profit Margin - 5 Yr. Avg. | -32.24 | 10.75 | 5.58 | |
| Effective Tax Rate (TTM) | -- | 22.44 | 22.40 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 22.49 | 22.75 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 523,846 | 992,970,939 | 887,291,347 | |
| Net Income/Employee (TTM) | -76,158 | 114,017,310 | 101,845,047 | |
| Receivable Turnover (TTM) | 5.31 | 5.96 | 5.93 | |
| Inventory Turnover (TTM) | 0.58 | 2.62 | 3.36 | |
| Asset Turnover (TTM) | 0.34 | 0.97 | 0.94 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | -4.91 | 11.51 | 11.17 | |
| Return on Assets - 5 Yr. Avg. | -9.67 | 12.96 | 12.34 | |
| Return on Investment (TTM) | -5.48 | 14.89 | 14.48 | |
| Return on Investment - 5 Yr. Avg. | -10.78 | 16.86 | 16.02 | |
| Return on Equity (TTM) | -7.41 | 16.01 | 15.78 | |
| Return on Equity - 5 Yr. Avg. | -15.23 | 17.66 | 17.01 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | 25.50 | 26.75 | 20.40 |
| EPS (TTM) % | -253.66 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Biomarin Pharmaceutical Inc
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | 5.23 | 1.60 | 99 | 25 |
| 13 Week | 4.75 | -0.35 | 99 | 42 |
| 26 Week | 7.80 | -0.39 | 99 | 42 |
| 52 Week | 2.35 | -13.25 | 99 | 12 |
| YTD | 14.45 | 0.51 | 99 | 37 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
Institutional Holders
| % Shares Owned: | 0.00% |
| # of Holders: | 713 |
| Total Shares Held: | 181,645,934 |
| 3 Mo. Net Change: | -391,508 |
| # New Positions: | 70 |
| # Closed Positions: | 65 |
| # Increased Positions: | 290 |
| # Reduced Positions: | 297 |
| # Net Buyers: | -7 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.